Akorn Says FDA Report Rehashes Data From Fresenius Trial
In a letter to a Delaware vice chancellor made public Monday, Akorn Inc. said that a recent inspection of the drugmaker's New Jersey facility by federal regulators identified areas of concern that...To view the full article, register now.
Already a subscriber? Click here to view full article